CLL Coverage from Every Angle

Jennifer R. Brown, MD, PhD, on Using Venetoclax and Rituximab in Chronic Lymphocytic Leukemia

Posted: Monday, September 16, 2019

How is minimal residual disease negativity used to evaluate the effectiveness of treatments in CLL such as venetoclax plus rituximab?

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.